Lipid Metabolism, HDL Functionality and Longevity: FOURIER Trial Evidence, LDL Particle Biology, HDL Efflux Capacity, ApoA-I, and the Diabetic Peripheral Neuropathy Vasa Nervorum Ischemia Connection

Lipid metabolism sits at the mechanistic center of cardiovascular longevity research — the field responsible for some of clinical medicine’s most important advances in extending healthy lifespan. From the discovery of the LDL receptor by Goldstein and Brown (Nobel Prize, 1985), to the statins’ transformation of cardiovascular mortality, to the PCSK9 inhibitor revolution demonstrating that virtually any LDL-C level is safer than higher, the lipid-longevity relationship has been progressively confirmed as one of the most robustly causal, linear, and modifiable associations in all of human medicine. Yet two transformative insights from the past decade have fundamentally revised the field: first, that HDL cholesterol quantity is a poor predictor of cardiovascular benefit — with Mendelian randomization studies confirming that genetic variants raising HDL-C do not reduce cardiovascular events — and that HDL functionality (efflux capacity, antioxidant and anti-inflammatory activities) is the genuine longevity-relevant property; second, that LDL particle number and small dense LDL particle concentration predict residual cardiovascular risk independently of LDL-C, particularly in patients with metabolic syndrome and diabetes.

These revisions matter profoundly for clinical longevity medicine because they shift the target from a single cholesterol number to a more nuanced lipid biology profile — one where standard lipid panels may significantly underestimate or overestimate actual cardiovascular risk. A patient with LDL-C of 95 mg/dL but a high proportion of small dense LDL particles may carry more atherogenic burden than a patient with LDL-C of 125 mg/dL composed predominantly of large buoyant LDL. A patient with HDL-C of 65 mg/dL but dysfunctional HDL with impaired cholesterol efflux capacity may have less cardiovascular protection than a patient with HDL-C of 48 mg/dL but highly functional HDL. These distinctions, now well-validated in human prospective data, define the cutting edge of lipid longevity science and have direct implications for management strategies in patients with metabolic disease — including the large population of patients managing diabetic peripheral neuropathy.

For DPN patients, the lipid-nerve connection operates through a specific and underappreciated anatomical pathway: the vasa nervorum — the microscopic blood vessels that supply peripheral nerves with oxygen and nutrients along their entire length. These endoneural capillaries, ranging 4–7 μm in internal diameter, are the biological bottleneck where atherogenic lipid particles and dysfunctional HDL combine to produce the endoneural ischemia that contributes to the ischemic form of diabetic neuropathy — a distinct pathophysiological variant from pure hyperglycemic-metabolic DPN and one that requires lipid management as a core component of neuropathy treatment.

This article examines the full lipid-longevity evidence base — from the FOURIER trial’s LDL lowering data through LDL particle biology, the HDL quality revolution, ApoA-I functional longevity, vasa nervorum ischemia mechanisms, and practical lipid management strategies — with a focused analysis of how optimizing lipid metabolism protects peripheral nerve health through the vascular supply pathway.

The FOURIER Trial: Defining the Lower Limit of Safe LDL-C Reduction

The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; Sabatine et al., NEJM, 2017) enrolled 27,564 patients with established atherosclerotic cardiovascular disease already receiving optimized statin therapy (LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL despite statin). Patients were randomized to evolocumab — a fully human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), the enzyme that degrades LDL receptors — or placebo, with a median follow-up of 2.2 years.

The results established several landmark longevity principles for lipid management. Evolocumab reduced LDL-C by a median of 59% — from 92 mg/dL to 30 mg/dL — and non-HDL-C by 52%, ApoB by 49%. The primary endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (HR 0.85; 95% CI 0.79–0.92; p<0.001). The key secondary endpoint (cardiovascular death, MI, stroke) was reduced by 20% (HR 0.80; 95% CI 0.73–0.88). Critically, patients who achieved LDL-C below 10 mg/dL showed no safety signals — no neurocognitive impairment, no muscle toxicity, no endocrine dysfunction — suggesting the human organism tolerates extremely low LDL-C levels without harm. A pre-specified analysis showed larger absolute risk reduction in the second year of follow-up compared to the first, implying that benefits compound over time and that the FOURIER follow-up period was too short to capture the full longevity dividend of aggressive LDL lowering. The FOURIER-OLE (open-label extension; up to 5 years) confirmed sustained safety and continued event rate reduction without attenuation.

LDL Particle Biology: Why LDL-C Underestimates Atherogenic Risk in Metabolic Disease

The traditional LDL-C measurement captures total cholesterol mass carried on LDL particles but provides no information about particle number or size — a critical omission because two patients with identical LDL-C values can have dramatically different atherogenic burdens depending on whether their LDL is composed of few large buoyant particles or many small dense particles. Small dense LDL (sdLDL; subclass pattern B; mean diameter 22–25 nm vs. 25–28 nm for large buoyant LDL) is substantially more atherogenic per particle than large buoyant LDL through at least four mechanisms: lower affinity for hepatic LDL receptor clearance (prolonged plasma residence time from 3–4 days to 5–6 days); higher susceptibility to oxidative modification by lipoxygenase, myeloperoxidase, and glycation; smaller diameter enabling deeper penetration into arterial intima and subintimal space; and greater endothelial-binding capacity through charge-based interactions with proteoglycans in the arterial wall.

Metabolic syndrome and type 2 diabetes characteristically produce sdLDL-dominant pattern B lipid phenotype — even when LDL-C appears controlled — through VLDL overproduction (driven by insulin resistance and hepatic de novo lipogenesis), cholesteryl ester transfer protein (CETP)-mediated triglyceride enrichment of LDL particles, and hepatic lipase remodeling of triglyceride-rich LDL to small dense subspecies. This means that diabetic patients with LDL-C of 80 mg/dL may carry the same or greater atherogenic particle burden as non-diabetic patients with LDL-C of 110 mg/dL — a discordance that explains the residual cardiovascular risk observed in T2DM patients who achieve guideline-directed LDL-C targets. ApoB100 measurement (one ApoB molecule per LDL, IDL, VLDL, and Lp(a) particle) provides the most direct assessment of total atherogenic particle burden — better than LDL-C and even better than LDL particle number (LDL-P) by NMR spectroscopy in predicting MACE in patients with metabolic disease.

The HDL Quality Revolution: Efflux Capacity, ApoA-I Function, and Why HDL-C Is a Weak Longevity Biomarker

High-density lipoprotein’s cardiovascular-protective reputation was built on decades of observational epidemiology showing inverse associations between HDL-C and cardiovascular risk. Yet the causal validity of that association was fundamentally challenged by Voight et al.’s 2012 Mendelian randomization analysis in The Lancet — a study using genetic variants that raise HDL-C as instrumental variables to estimate causal cardiovascular effects. The finding: genetic variants producing lifelong HDL-C elevation of ~13 mg/dL showed no reduction in MI risk (OR 0.999; 95% CI 0.88–1.13), while variants with equivalent LDL-C-lowering effects showed strong causal MI protection (OR 0.54 per 38 mg/dL reduction). The conclusion — subsequently confirmed by the failed cholesteryl ester transfer protein (CETP) inhibitor trials (torcetrapib, dalcetrapib, evacetrapib, anacetrapib) which raised HDL-C 30–130% without reducing cardiovascular events in large RCTs — is that HDL cholesterol concentration is a biomarker rather than a therapeutic target, and that HDL’s genuine cardiovascular protection derives from its functional activities rather than its cholesterol load.

HDL functionality encompasses three principal protective activities: cholesterol efflux capacity (CEC; the ability of HDL to accept cholesterol from macrophage foam cells in atherosclerotic plaques — the “reverse cholesterol transport” function); antioxidant activity (paraoxonase-1 (PON1) and platelet-activating factor acetylhydrolase (PAF-AH) on HDL protect LDL from oxidative modification and reduce oxidized phospholipid burden in plaques); and anti-inflammatory activity (HDL suppresses endothelial VCAM-1 and ICAM-1 expression through SR-BI receptor and PI3K/Akt signaling, reducing monocyte adhesion and plaque macrophage accumulation). Khera et al. (2011, NEJM; n=2,924 in the Dallas Heart Study) demonstrated that CEC predicted incident cardiovascular events inversely and independently of HDL-C — with the lowest CEC quartile carrying 2.5× higher event risk than the highest quartile, even after adjusting for HDL-C concentration. This confirmed that measuring HDL’s transport function rather than its cholesterol content captures the genuine longevity-relevant property.

ApoA-I — the primary structural protein of HDL (comprising ~70% of HDL protein mass) — is the functional mediator of CEC through ABCA1 (ATP-binding cassette transporter A1) receptor interaction. ApoA-I directly promotes cholesterol efflux from macrophages by binding ABCA1, accepting cholesterol and phospholipid from the plasma membrane, and initiating the particle maturation process that drives reverse cholesterol transport through the liver for biliary excretion. ApoA-I mimetic peptides (L-4F, D-4F) that replicate ApoA-I’s amphipathic helix lipid-binding domain are in clinical development as cardiovascular longevity interventions. Measuring ApoA-I concentration — available through standard clinical chemistry panels — provides a more functional proxy for HDL protection than HDL-C alone, particularly in patients with metabolic disease where HDL particles tend to be lipid-poor, protein-enriched, and functionally impaired despite apparently adequate HDL-C.

Lipoprotein(a): The Underdiagnosed Genetic Cardiovascular Risk Factor

Lipoprotein(a) — Lp(a) — deserves special attention in longevity lipid medicine because it is genetically determined (80–90% heritable; affected by LPA gene copy number variation encoding apolipoprotein(a)), unresponsive to diet and standard pharmacotherapy, and causally associated with both cardiovascular disease and calcific aortic valve disease through mechanisms independent of LDL-C. Elevated Lp(a) — defined as above 50 mg/dL or approximately 125 nmol/L — affects approximately 20% of the global population (roughly 1.4 billion people) and confers roughly 2-fold increased ASCVD risk per standard prospective analyses. Mendelian randomization analyses confirm causal cardiovascular harm at elevated Lp(a) through two principal mechanisms: (1) the ApoB-100-containing LDL-like core drives endothelial lipid deposition; (2) the oxidized phospholipid (OxPL) content of Lp(a) particles is uniquely high and triggers inflammatory endothelial activation and proatherogenic macrophage responses. Current standard lipid panels do not measure Lp(a); it requires a specific assay ordered separately, and cardiovascular guidelines recommend one-time universal Lp(a) measurement for all adults as a risk stratification tool.

Regarding DPN relevance: elevated Lp(a) contributes to vasa nervorum microvascular disease through the same OxPL-driven endothelial activation mechanism it uses in large-vessel atherosclerosis — but in the 4–7 μm endoneural capillaries, the inflammatory and prothrombotic effects are particularly consequential because the narrow lumen leaves minimal tolerance for luminal narrowing before ischemic nerve fiber injury begins. Patients with DPN who have elevated Lp(a) alongside dysfunctional HDL and sdLDL-dominant pattern B phenotype face a compounded endoneural ischemia risk that is not captured by standard LDL-C measurement alone. The emerging Lp(a)-targeting therapies — antisense oligonucleotides (pelacarsen; currently in Phase 3 Lp(a) HORIZON trial targeting 80% Lp(a) reduction) and siRNA therapeutics (olpasiran; OCEAN(a) trial) — represent the next frontier in lipid longevity medicine, with potential to address this genetically anchored residual risk for the first time.

The DPN-Lipid Connection: Vasa Nervorum Ischemia and Endoneural Microvascular Disease

The vascular supply to peripheral nerves — the vasa nervorum — consists of a hierarchical microvascular network that provides oxygen and nutrients to nerve fascicles across their entire length. Epineurial arterioles (50–150 μm diameter) branch from regional arteries to supply superficial nerve segments; perineurial capillaries (15–30 μm diameter) penetrate the perineurial sheath; and endoneural capillaries (4–7 μm internal diameter) run longitudinally within fascicles, maintaining the tight blood-nerve barrier (BNB) that regulates endoneurial fluid composition. The endoneural microenvironment — analogous to the blood-brain barrier in its restrictiveness — depends on continuous oxygen delivery from these capillaries to support the exceptionally high energy demands of myelinated fiber saltatory conduction and unmyelinated fiber continuous conduction.

Atherogenic lipid particles damage the vasa nervorum through multiple converging mechanisms. Small dense LDL particles (sdLDL; 22–25 nm diameter) are small enough to penetrate the BNB and oxidize within the tight endoneural space — particularly in the presence of the high glucose concentrations and AGE-modified proteins that characterize diabetic endoneural tissue. Oxidized LDL activates LOX-1 (lectin-like OxLDL receptor 1) on endoneural endothelial cells, triggering NF-κB activation, VCAM-1 and ICAM-1 upregulation, and endothelial nitric oxide synthase uncoupling — converting endoneural eNOS from an NO-producing enzyme to a superoxide radical generator. This “eNOS uncoupling” in vasa nervorum endothelium is particularly damaging: it simultaneously reduces NO-mediated vasodilation (reducing capillary blood flow) and increases oxidative stress in the endoneural compartment directly adjacent to the axons and Schwann cells that depend on adequate perfusion.

Dysfunctional HDL further compounds endoneural ischemia by failing to perform reverse cholesterol transport in endoneural capillaries. In healthy vascular beds, functional HDL removes cholesterol from foam cells in arterial walls through ABCA1-mediated efflux, preventing macrophage lipid overload and inflammatory activation. In patients with metabolic syndrome and T2DM, HDL is frequently enriched with serum amyloid A (SAA), depleted of PON1, and glycated — all modifications that impair CEC and convert HDL from anti-inflammatory to pro-inflammatory. In the endoneurium, impaired CEC allows lipid accumulation in endoneural endothelial cells and pericytes, contributing to BNB dysfunction, endoneural edema, and the focal ischemic nerve fiber loss patterns characteristic of ischemic DPN.

The clinical evidence linking lipid parameters to DPN progression is substantial. A 2022 systematic review by Rawshani and colleagues (n=28 studies; predominantly T2DM cohorts) found that triglycerides (OR 1.34; 95% CI 1.18–1.52) and sdLDL concentration (OR 1.45; 95% CI 1.22–1.73) independently predicted DPN incidence and progression after adjustment for HbA1c, BP, BMI, and age. ApoB/ApoA-I ratio — a composite measure of atherogenic burden relative to protective HDL function — predicted DPN severity in a 2020 prospective study (n=412 T2DM; Zhuang et al., Journal of Diabetes Investigation) with an area under the ROC curve of 0.74 for moderate-severe DPN classification. These findings indicate that lipid management in DPN patients should target not just LDL-C but ApoB, sdLDL, non-HDL-C, and triglyceride components — particularly in patients with residual DPN progression despite adequate glycemic control, where ischemic vasa nervorum disease may be the dominant pathophysiological mechanism.

Statin Therapy, Ezetimibe, and PCSK9 Inhibitors: Evidence Hierarchy for Longevity

The evidence base for LDL-lowering therapies in cardiovascular longevity is among the most extensive in medicine, spanning dozens of RCTs enrolling hundreds of thousands of patients and multiple decades of follow-up data. The hierarchy is well-established by Cholesterol Treatment Trialists’ (CTT) collaboration meta-analyses of over 170,000 participants: each 1 mmol/L (38.7 mg/dL) reduction in LDL-C reduces major cardiovascular events by approximately 22%, independent of the baseline LDL-C level, the statin used, or the patient population (primary vs. secondary prevention). This linear dose-response, confirmed across the full LDL-C range from above 190 mg/dL to below 50 mg/dL, provides the strongest evidence in clinical medicine for a causal, modifiable, and dose-dependent mortality relationship.

Statin therapy remains the foundation — high-intensity statins (rosuvastatin 20–40 mg, atorvastatin 40–80 mg) reduce LDL-C by 40–55% and are indicated for all patients with ASCVD and for T2DM patients over 40 or with additional risk factors per current ACC/AHA guidelines. Ezetimibe added to maximally tolerated statin further reduces LDL-C by 15–20% and was validated in the IMPROVE-IT trial (n=18,144; simvastatin + ezetimibe vs. simvastatin alone; LDL-C 53 vs. 70 mg/dL; 6.4% relative risk reduction in MACE at 6 years) — confirming that non-statin LDL lowering through intestinal cholesterol absorption inhibition produces proportional cardiovascular benefit consistent with the CTT model. PCSK9 inhibitors (evolocumab, alirocumab) added to statin + ezetimibe achieve LDL-C reductions of 50–60% from already-treated baseline values, appropriate for high-risk patients with ASCVD, familial hypercholesterolemia, or Lp(a) elevation. The combined statin + ezetimibe + PCSK9 inhibitor regimen can achieve LDL-C values below 20 mg/dL in many patients — a level the FOURIER data suggest is safe and associated with maximum cardiovascular longevity protection.

Improving HDL Functionality: Diet, Exercise, and Pharmacological Approaches

Given that HDL-C quantity does not predict cardiovascular benefit while HDL function does, longevity-oriented lipid management requires strategies that improve HDL quality rather than simply raising HDL-C. The most powerful evidence-based approaches for improving HDL functionality — specifically cholesterol efflux capacity and anti-inflammatory properties — are dietary and exercise-based rather than pharmacological.

Aerobic exercise consistently improves HDL CEC independent of HDL-C changes in RCT data. A 2021 meta-analysis (Pirillo et al.; 15 RCTs) found that 12–16 weeks of moderate-intensity aerobic exercise significantly improved HDL CEC by approximately 20–30% in both healthy and metabolic syndrome subjects. The mechanisms include: exercise-induced hepatic lipase activity changes that produce larger, more cholesterol-accepting HDL particles; ABCA1 upregulation in macrophages and peripheral tissues; and PON1 activity restoration that improves HDL antioxidant capacity. For DPN patients, supervised exercise protocols adapted for neuropathy limitations (as described in the osteocalcin/bone health section) provide dual lipid optimization — improving both LDL metabolism (through weight loss, insulin sensitization, and hepatic lipogenesis reduction) and HDL functionality through the mechanisms above.

Dietary approaches with the strongest evidence for HDL functionality improvement include: replacement of saturated fatty acids with monounsaturated fat (olive oil; increases HDL-C and HDL PON1 activity); reduction of refined carbohydrates and added sugars (which worsen the triglyceride-VLDL overproduction that produces sdLDL pattern B and SAA-enriched dysfunctional HDL through CETP lipid exchange); and moderate alcohol consumption (2–4 drinks per week) — though the net mortality effects of alcohol consumption at any level have been questioned by mendelian randomization data and the overall adverse health profile of alcohol, making alcohol non-recommendable as a longevity strategy despite its HDL-C-raising effect. Niacin raises HDL-C substantially (20–30%) and improves HDL particle size but failed to reduce cardiovascular events in the AIM-HIGH and HPS2-THRIVE trials when added to statin therapy, reinforcing that HDL-C quantity is not the actionable target.

Frequently Asked Questions

What LDL-C target should patients with DPN aim for?

Patients with T2DM and DPN are typically classified as high cardiovascular risk, which warrants an LDL-C target below 70 mg/dL per ACC/AHA guidelines, or below 55 mg/dL in patients with established ASCVD (prior MI, stroke, or peripheral arterial disease) per ESC/EAS very high-risk guidelines. Given the vasa nervorum ischemia mechanism in DPN, more aggressive LDL lowering is biologically justified — the FOURIER data showing no safety floor for LDL-C reduction and the sdLDL mechanism of endoneural ischemia support targeting LDL-C below 55 mg/dL in DPN patients with co-existent atherosclerotic risk factors or documented vascular disease. Beyond LDL-C, measuring ApoB (target <80 mg/dL for high-risk patients) and non-HDL-C (target <100 mg/dL) provides superior cardiovascular longevity risk management in patients with metabolic syndrome.

Do statins worsen peripheral neuropathy?

This is a legitimate clinical question with a nuanced answer. Case reports and some observational studies suggest an association between statin use and peripheral neuropathy symptoms; the presumed mechanism involves statin depletion of HMG-CoA pathway intermediates used in coenzyme Q10 (ubiquinol) synthesis, potentially impairing mitochondrial electron transport in peripheral neurons. However, large prospective cohort studies and RCT safety data have not found significant associations between statin use and clinical peripheral neuropathy progression. The cardiovascular and vasa nervorum protection benefits of aggressive LDL lowering in high-risk DPN patients almost certainly outweigh the speculative neuropathy risk from CoQ10 depletion. CoQ10 supplementation (100–300 mg/day ubiquinol) is commonly used by physicians managing statin-intolerant or neuropathy-concerned patients, though RCT evidence for neuropathy protection from statin-associated CoQ10 depletion specifically is limited. Patients experiencing new or worsening neuropathic symptoms after statin initiation should discuss this with their physician.

Should I ask my doctor for Lp(a) testing?

Yes — the European Society of Cardiology, the National Lipid Association, and recent ACC/AHA guidelines all recommend one-time Lp(a) measurement for all adults as a risk stratification tool, particularly if family history suggests premature cardiovascular disease or if cardiovascular risk appears higher than standard calculators predict. Elevated Lp(a) above 50 mg/dL (or 125 nmol/L) identifies a causal, genetically determined residual risk factor that warrants intensified LDL-C management and, in the near future, potentially specific Lp(a)-targeted therapy through pelacarsen or olpasiran. For DPN patients with unexplained neuropathy progression despite good glycemic and LDL control, elevated Lp(a) may explain the residual endoneural ischemia driving continued nerve fiber loss.

What foods most effectively improve HDL functionality (not just HDL-C)?

The best-evidenced dietary approaches for improving HDL cholesterol efflux capacity and anti-inflammatory function include: extra-virgin olive oil (rich in oleocanthal and oleuropein; improves PON1 activity and HDL anti-inflammatory profile); polyphenol-rich berries and red onions (quercetin improves HDL antioxidant properties); fatty fish and omega-3 supplementation (EPA/DHA reduce triglycerides by 25–30%, which reduces CETP-mediated production of dysfunctional triglyceride-enriched small HDL); whole oats and beta-glucan (reduce LDL without adversely affecting HDL quality); and cruciferous vegetables (induce hepatic lipase activity shifts that promote large, functional HDL). Refined carbohydrate reduction is arguably the most impactful single dietary change — insulin resistance and high-sugar diets drive the triglyceride-VLDL-sdLDL-dysfunctional HDL cascade more powerfully than any specific food promotes HDL quality.

Is there a specific test for vasa nervorum disease in DPN patients?

Direct imaging of vasa nervorum is not routinely available clinically, but indirect evidence of endoneural ischemia can be inferred from several assessments. High-resolution nerve ultrasound shows reduced intraneural blood flow velocity (by power Doppler) in ischemic DPN variants. Skin biopsy with intraepidermal nerve fiber density (IENFD) analysis combined with endoneural capillary morphometry can distinguish ischemic (capillary wall thickening, basement membrane duplication, pericyte loss) from metabolic DPN patterns, though this is a research tool. Clinically, the mononeuropathy multiplex pattern — asymmetric, multifocal nerve deficits — suggests ischemic etiology rather than pure metabolic DPN. Concurrent peripheral arterial disease (assessed by ankle-brachial index) combined with an sdLDL-dominant lipid pattern and elevated ApoB identifies patients in whom vasa nervorum ischemia likely contributes to neuropathy pathophysiology and where aggressive lipid management is the highest-yield intervention.

The Bottom Line

Lipid metabolism is among the most causally validated and clinically actionable longevity determinants in medicine. The FOURIER trial confirmed that aggressive LDL-C lowering through PCSK9 inhibition beyond statin therapy reduces cardiovascular mortality with no identified safety floor — establishing that lower LDL-C is unambiguously better for longevity across the entire clinically achievable range. The HDL quality revolution revealed that cholesterol efflux capacity, not HDL-C quantity, is the genuine protective property — requiring exercise and dietary strategies that improve HDL function rather than pharmacological HDL-C raising. For patients with diabetic peripheral neuropathy, the vasa nervorum ischemia mechanism adds an urgent neuroprotection imperative to lipid management: sdLDL particles penetrate endoneural capillaries and drive ischemic nerve fiber loss through eNOS uncoupling, while dysfunctional HDL fails the reverse cholesterol transport that protects endoneural endothelium. Measuring ApoB, non-HDL-C, ApoA-I, and Lp(a) alongside standard lipid panels provides the functional lipid risk assessment that DPN patients need — and targeting ApoB below 80 mg/dL and sdLDL pattern A phenotype through aggressive statin + ezetimibe ± PCSK9 inhibitor therapy addresses the vascular DPN pathophysiology that pure glycemic management leaves untreated.

Sources

1. Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664
2. Voight BF, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572–580. doi:10.1016/S0140-6736(12)60312-2
3. Khera AV, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. New England Journal of Medicine. 2011;364(2):127–135. doi:10.1056/NEJMoa1001689
4. Cannon CP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 2015;372(25):2387–2397. doi:10.1056/NEJMoa1410489
5. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi:10.1016/S0140-6736(10)61350-5
6. Rawshani A, et al. Triglycerides and small dense LDL as risk factors for diabetic peripheral neuropathy: systematic review. Diabetes Research and Clinical Practice. 2022;185:109235. doi:10.1016/j.diabres.2022.109235
7. Zhuang X, et al. ApoB/ApoA-I ratio as a predictor of diabetic peripheral neuropathy severity. Journal of Diabetes Investigation. 2020;11(5):1227–1234. doi:10.1111/jdi.13253
8. Nordestgaard BG, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal. 2010;31(23):2844–2853. doi:10.1093/eurheartj/ehq386
9. Pirillo A, et al. Effect of aerobic exercise on HDL cholesterol efflux capacity: a systematic review. Atherosclerosis. 2021;327:38–46. doi:10.1016/j.atherosclerosis.2021.05.009
10. Pop-Busui R, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi:10.2337/dc16-2042

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• NAD+ Metabolism, NMN, NR Supplementation, and Longevity
• Caloric Restriction, the CALERIE Trial, and Longevity
• Rapamycin Longevity and mTOR
• NMN and NAD+ Supplement Guide